Modified Citrus Pectin fights the spread of cancer by preventing or inhibiting metastases.

MCP is sticky, which is why pectin is used in making jellies. It turns out that cancer cells are particularly susceptible to having Modified Citrus Pectin attach to them because of the nature of their cell membranes. Once the Modified Citrus Pectin has attached itself to the cancer cells floating in the blood stream, the cancer cells become coated and unable to attach themselves to the lining of blood vessels or other potential metastatic sites. This process can only occur in the bloodstream, hence the importance of allowing the short chained pectin to be absorbed by the body.

Studies in humans are now verifying the effectiveness of this substance. One researcher said that it appears to slow the PSA doubling time in prostate cancer patients. An independent clinic reported, "of nine individuals without metastasis at the beginning of the recorded period, six had not metastasis during the 18 month period...none had metastatic site development after 7
months consuming modified citrus pectin."

DOSE

According to one distributing company, Natural Health Consultants, the dose is 15 grams per day. Stirring briskly, dissolve 2 level teaspoonfuls of powder in water, juice, or other liquid drink 3 times daily or as directed by a physician. The capsules at NHC are 500 mg and their recommended dose as a dietary supplement is 3 to 6 capsules per day, though this may be inadequate for its anti metastatic properties.

The following is an abstract from an article on the anti-metastatic efficacy of Modified Citrus Pectin.
A New Approach to Metastatic Cancer Prevention: Modified Citrus Pectin (MCP), A Unique Pectin that Blocks Cell Surface Lectins

by Parris M. Kidd, PhD

Citrus pectin (CP) is a commercially available, water-soluble fiber with proven health benefits. The branching polysaccharide structure of CP can be altered to produce a lower molecular weight, galactose-rich, modified citrus pectin (MCP) which has unique properties. Specifically, MCP, but not CP, might help retard cancer metastasis by combining with an array of galactose-specific proteins on the cancer cell surface called galectins (for galactose-specific lectins). As with many human cancer cell lines that have been studied, the potentially metastatic B16-F1 (mouse melanoma) and MLL (rat prostate) cells carry galectins, cell surface proteins that bind to galactose on neighboring cancer cells and oligosaccharides on the host cell surface. MCP inhibits metastasis by the cells in the mouse and the rat, respectively. Unlike the much larger CP polysaccharide, galactose-rich MCP may be small enough to access and bind
tightly with galectins on the cancer cell surface, saturating the galactose binding sites of the cancer cell lectins, and thereby inhibiting both aggregation of tumor cells and adhesion to normal cells. Thus deprived of adhesion, the cancer cells fail to metastasize. Undeniably, important gaps still exist in the current understanding of MCP's clinical efficacy and its mode(s) of action. But MCP's apparent safety and proven anti-metastatic action, and the lack of proven therapies against metastasis, together may justify its inclusion into comprehensive orthomolecular anticancer regimens. (Alt Med Rev 1996;1:4-10.)

In animal studies modified citrus pectin inhibited spontaneous pulmonary
metastases. The ability of cells to metastasize appears to be related, in part, to the cohesiveness between cells. In other words, for a tumor to spread it may require a clump of cells rather than a single cell or a few cells together. Cellular interactions are mediated by a carbohydrate-binding protein at the cell surface called galectin-3. In human studies there is a correlation between the level of galectin expression and tumor stage. This has been found in human colorectal, gastric and thyroid cancers. In agarose cell cultures, anti-galectin monoclonal antibodies inhibit the growth of tumor cells (Raz et al, Cancer Metastasis Rev 6:433-452,1987).
Citrus pectin is a natural fiber, found in the 'pulp' of oranges and grapefruits. Dr. Pienta developed an acid process to break down the pectin into microscopic pieces that are small enough to be absorbed into the bloodstream directly. Once having entered the bloodstream the 'modified' pectin attaches itself to tumor cells and prevents them from metastasis.
There have not been enough controlled human studies with MCP for mainstream medicine to accept it as an anti-cancer treatment. Should you consider it for yourself? Says Dr. Williams: "Since this modified citrus pectin has no ill effects, and you can take it with a glass of water, I wouldn't hesitate to use it now, especially if I were faced with an aggressive prostate tumor."
This product doesn't kill tumors, it doesn't shrink them, or prevent them from growing. However, what it does according to all the available reports, is equally important: it prevents cancer from spreading in the body.
NAME OF THE PRODUCT: Modified Citrus Pectin
SOURCES:
C. J. Patton Center 151 Mifflin Road Miller's Burg PA 17061 Tel: 717-362-2067 Fax: 717-362-3757
Natural Health Consultants

P.O. Box 1091
Vallejo, California 94590

Toll free: 888 852-4993
Info: 707 554-1820
Fax: 707 647-3055

Klabin Marketing
2067 Broadway, Ste #700, New York NY 10023
Tel: 800-933-9440 or 212-877-3632
COST: Approx. $90 per month